Skip to main content

Advertisement

Log in

Risk management adherence following genetic testing for hereditary cancer syndromes: a Singaporean experience

  • Short Communication
  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

Assessing adherence behavior among mutation carriers to cancer risk management guidelines is important for both service improvement and cost-effectiveness analyses, but such real-world data is often lacking. The present study aims to report adherence rates among mutation carriers in a recently established cancer genetics program in Singapore. We conducted a medical chart review of mutation carriers who had attended for genetic counseling and gathered data regarding risk management behavior, including cancer surveillance and/or risk-reducing surgery, and cancers subsequently detected. Of the 52 subjects included in the study, the majority were affected prior to genetic testing (78.8%) and had family history suggestive of a germline mutation (88.5%). The overall adherence rate was 96.2%, including 37 (74.0%) fully-adherent and 13 (26.0%) partially-adherent subjects, with five cancers subsequently detected. Among the 28 BRCA1/2 mutation carriers, adherence to breast cancer risk management was also high (89.3%), although uptake of risk-reducing bilateral salpingo-oophorectomy was not as common (60%). Whilst overall adherence in this cohort was high, BRCA1/2 mutation carriers may require targeted interventions to improve ovarian cancer risk management uptake. Additionally, further education among health professionals and the wider community regarding cancer genetics is needed to ensure the early identification of mutation carriers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

References

  1. Leenen CHM, Goverde A, de Bekker-Grob EW et al (2016) Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age. Genet Med 18:966–973. https://doi.org/10.1038/gim.2015.206

    Article  PubMed  Google Scholar 

  2. Li S-T, Yuen J, Zhou K et al (2017) Impact of subsidies on cancer genetic testing uptake in Singapore. J Med Genet 54:254–259. https://doi.org/10.1136/jmedgenet-2016-104302

    Article  PubMed  Google Scholar 

  3. Schneider KI, Schmidtke J (2014) Patient compliance based on genetic medicine: a literature review. J Community Genet 5:31–48. https://doi.org/10.1007/s12687-013-0160-2

    Article  PubMed  Google Scholar 

  4. Foster C, Watson M, Eeles R et al (2007) Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up. Br J Cancer 96:718–724. https://doi.org/10.1038/sj.bjc.6603610

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Schwartz MD, Isaacs C, Graves KD et al (2012) Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer 118:510–517. https://doi.org/10.1002/cncr.26294

    Article  PubMed  Google Scholar 

  6. Kwong A, Chu ATW, Wu CTS, Tse DMS (2014) Attitudes and compliance of clinical management after genetic testing for hereditary breast and ovarian cancer among high-risk Southern Chinese females with breast cancer history. Fam Cancer 13:423–430. https://doi.org/10.1007/s10689-014-9706-7

    Article  PubMed  Google Scholar 

  7. Buchanan AH, Voils CI, Schildkraut JM et al (2017) Adherence to recommended risk management among unaffected women with a BRCA Mutation. J Genet Couns 26:79–92. https://doi.org/10.1007/s10897-016-9981-6

    Article  PubMed  Google Scholar 

  8. Lerman C, Hughes C, Croyle RT et al (2000) Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 31:75–80. https://doi.org/10.1006/pmed.2000.0684

    Article  CAS  PubMed  Google Scholar 

  9. Garcia C, Wendt J, Lyon L et al (2014) Risk management options elected by women after testing positive for a BRCA mutation. Gynecol Oncol 132:428–433. https://doi.org/10.1016/j.ygyno.2013.12.014

    Article  PubMed  Google Scholar 

  10. Lammens CRM, Aaronson NK, Hes FJ et al (2011) Compliance with periodic surveillance for Von-Hippel-Lindau disease. Genet Med 13:519–527. https://doi.org/10.1097/GIM.0b013e3182091a1d

    Article  PubMed  Google Scholar 

Download references

Funding

Funding was provided by National Cancer Centre Community Cancer Fund.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Joanne Ngeow.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Eliza Courtney and Xin Wei Chin are joint first authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Courtney, E., Chin, X.W., Yuen, J. et al. Risk management adherence following genetic testing for hereditary cancer syndromes: a Singaporean experience. Familial Cancer 17, 621–626 (2018). https://doi.org/10.1007/s10689-018-0071-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-018-0071-9

Keywords

Navigation